ZEISS Ventures participated in the funding round of Hypervision Surgical
Applying hyperspectral imaging for intraoperative guidance to enable non-invasive tissue analysis
Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising £6.5 million. By harnessing AI and clinical edge computing, this King’s College London spin-out aims to revolutionise surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties.
ZEISS Ventures participated in Hypervision Surgical's seed funding round led by a syndicate of experienced European and American HealthTech investors, including HERAN Partners, Redalpine and LifeX Ventures.
"We are incredibly excited about the transformative potential of our Hyperspectral Intelligence platform," said Michael Ebner, CEO and co-founder of Hypervision Surgical. "Imagine a complex tumour surgery where surgeons can rely on precise measurements and tissue property information to distinguish between healthy and unhealthy tissue. Our technology makes the invisible visible, empowering surgeons to make confident decisions with enhanced precision and ultimately improving patient outcomes."
Hypervision Surgical’s platform promises dye-free visualization of otherwise invisible surgical structures and information in real time which is unique in this combination. The technology has the potential to become a standard feature commonly utilized in a wide range of surgical specialties like neurosurgery or spine surgery” explains Gerrit Schulte, Head of ZEISS Ventures.
About Hypervision Surgical
Hypervision Surgical Ltd, a spin-out from King's College London, is developing an intraoperative imaging system that seamlessly integrates into the surgical workflow for real-time tissue characterisation. Their goal is to revolutionise surgical outcomes through advanced computer-assisted analysis, enhancing precision and patient safety.
For more information, visit https://hypervisionsurgical.com/
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 8.8 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2022).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 13 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 40,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 31 March 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com